Abstract
Afala (ultralow-dose antibodies to prostate-specific antigen) injected for 60 days to rats with hormone-induced prostatitis caused by sulpiride prevented the development of prostatic hyperplasia and reduced the severity of histological changes. The effect of Afala was superior to that of the reference drug (Serenoa repens extract).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
G. G. Avtandilov, Medical Morphometry [in Russian], Moscow (1990).
L. M. Gorilovskii, Benign Prostatic Hyperplasia [in Russian], Ed. N. A. Lopatkin, Moscow (1999), pp. 12–20.
R. C. Bruskewitz, Rev. Urol., 5, No. 2, 72–80 (2003).
V. F. Coppenolle, C. Slomianny, F. Carpentier, et al., Am. J. Physiol. Endocrinol. Metab., 280, 120–129 (2001).
F. C. Lowe, C. G. Roehrborn, C. Robertson, and P. Boyle, J. Urol., 159, No. 2, 257 (1998).
M. Paubert-Braquet, J. P. Raynaud, P. Braquet, et al., Pharmacol. Res., 31, Suppl., 31–35 (1995).
Author information
Authors and Affiliations
Corresponding author
Additional information
__________
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 144, No. 11, pp. 542–544, November, 2007
Rights and permissions
About this article
Cite this article
Savelieva, K.V., Borovskaya, T.G., Kheyfets, I.A. et al. Comparative study of pharmacological activity of Afala on the model of hormone-induced prostatitis in rats. Bull Exp Biol Med 144, 699–701 (2007). https://doi.org/10.1007/s10517-007-0409-z
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10517-007-0409-z